Daniel Molin
About
Daniel Molin is a scholar working on Pathology and Forensic Medicine, Oncology and Immunology.
According to data from OpenAlex, Daniel Molin has authored 78 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Pathology and Forensic Medicine, 40 papers in Oncology and 18 papers in Immunology. Recurrent topics in Daniel Molin's work include Lymphoma Diagnosis and Treatment (66 papers), Viral-associated cancers and disorders (18 papers) and Lung Cancer Treatments and Mutations (14 papers). Daniel Molin is often cited by papers focused on Lymphoma Diagnosis and Treatment (66 papers), Viral-associated cancers and disorders (18 papers) and Lung Cancer Treatments and Mutations (14 papers). Daniel Molin collaborates with scholars based in Sweden, Denmark and United States. Daniel Molin's co-authors include Gunilla Enblad, Christer Sundström, John Radford, Craig H. Moskowitz, Margaret A. Shipp, Bastian von Tresckow, Vincent Ribrag, Pier Luigi Zinzani, Akihiro Tomita and Philippe Armand and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.
In The Last Decade
Daniel Molin
74 papers receiving 2.4k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Daniel Molin Sweden | 23 | 1.5k | 1.3k | 916 | 360 | 252 | 78 | 2.5k | ||
| Naomi Hunder United States | 17 | 1.5k 1.0× | 751 0.6× | 1.1k 1.2× | 301 0.8× | 282 1.1× | 35 | 2.5k | ||
| Kay M. Ristow United States | 31 | 1.7k 1.1× | 1.8k 1.4× | 616 0.7× | 417 1.2× | 487 1.9× | 76 | 2.9k | ||
| Jacques Bosq France | 31 | 1.2k 0.8× | 1.1k 0.9× | 620 0.7× | 302 0.8× | 245 1.0× | 74 | 2.5k | ||
| Joke W. Baars Netherlands | 23 | 935 0.6× | 899 0.7× | 505 0.6× | 349 1.0× | 507 2.0× | 52 | 2.4k | ||
| J. Bosq France | 28 | 1.2k 0.8× | 1.3k 1.0× | 560 0.6× | 382 1.1× | 276 1.1× | 70 | 2.8k | ||
| Andreas Zettl Germany | 30 | 1.1k 0.8× | 1.3k 1.0× | 490 0.5× | 646 1.8× | 438 1.7× | 72 | 2.7k | ||
| Ryo Ichinohasama Japan | 26 | 1.2k 0.8× | 1.6k 1.2× | 472 0.5× | 413 1.1× | 488 1.9× | 154 | 2.9k | ||
| Ayoma D. Attygalle United Kingdom | 22 | 885 0.6× | 1.3k 1.0× | 469 0.5× | 149 0.4× | 324 1.3× | 83 | 2.0k | ||
| Janet Matthews United Kingdom | 21 | 1.2k 0.8× | 1.6k 1.2× | 636 0.7× | 206 0.6× | 695 2.8× | 48 | 2.2k | ||
| Luís Colomo Spain | 25 | 1.6k 1.1× | 1.9k 1.4× | 779 0.9× | 317 0.9× | 501 2.0× | 66 | 2.7k |
Countries citing papers authored by Daniel Molin
Since
Specialization
Citations
This map shows the geographic impact of Daniel Molin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Molin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Molin more than expected).
Fields of papers citing papers by Daniel Molin
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Daniel Molin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Molin. The network helps show where Daniel Molin may publish in the future.
Co-authorship network of co-authors of Daniel Molin
This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Molin. A scholar is included among the top collaborators of Daniel Molin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Molin. Daniel Molin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Fosså, Alexander, Daniel Molin, Paul J. Bröckelmann, et al.. (2025). Brentuximab vedotin monotherapy is a feasible and effective treatment for older patients with classical Hodgkin lymphoma unsuitable for curative chemotherapy: Results from the prospective GHSG–NLG phase II BVB trial. HemaSphere. 9(3). e70099–e70099.
2.
Viviani, Simonetta, Chiara Pavoni, Sally F. Barrington, et al.. (2025). Advanced stage classical Hodgkin lymphoma patients with a positive interim-PET (PET-2) Deauville score 5 after 2 ABVD cycles: a pooled analysis of three multicenter trials. Blood Cancer Journal. 15(1). 165–165.
3.
Ekberg, Sara, Karin E. Smedby, Tobias Sjöblom, et al.. (2024). Evaluation of coverage, generalisability and validity of the U‐CAN lymphoma biobank in Sweden: A comparison with nationwide registers. British Journal of Haematology. 205(5). 1794–1803.
4.
Weibull, Caroline E., Karin E. Smedby, Lasse Jakobsen, et al.. (2023). Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway—A population‐based matched cohort study. International Journal of Cancer. 153(4). 723–731.
5.
Armand, Philippe, Pier Luigi Zinzani, Hun Ju Lee, et al.. (2023). Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed/refractory classical Hodgkin lymphoma. Blood. 142(10). 878–886.
6.
Fohlin, Helena, Gunilla Enblad, Bengt Glimelius, et al.. (2022). Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy. Journal of Clinical Oncology. 40(13). 1487–1496.
7.
Shen, Qiujin, Daniel Molin, Eva Freyhult, et al.. (2022). Plasma protein biomarker profiling reveals major differences between acute leukaemia, lymphoma patients and controls. New Biotechnology. 71. 21–29.
8.
Andersson, Anne, Beatrice Melin, Gunilla Enblad, et al.. (2021). High risk of cardiovascular side effects after treatment of Hodgkin’s lymphoma – is there a need for intervention in long-term survivors?. Upsala Journal of Medical Sciences. 126(1).
9.
Venge, Per, et al.. (2021). Serum concentrations of Thymidine kinase 1 measured using a novel antibody-based assay in patients with Hodgkin Lymphoma. Upsala Journal of Medical Sciences. 126(1).
10.
Gormsen, Lars Christian, Peter Kamper, Cecilia Wassberg, et al.. (2019). Focal skeletal FDG uptake indicates poor prognosis in cHL regardless of extent and first‐line chemotherapy. British Journal of Haematology. 186(3). 431–439.
11.
Holte, Harald, Ingrid Glimelius, Magnus Björkholm, et al.. (2019). No excess long‐term mortality in stage I‐IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy. British Journal of Haematology. 188(5). 685–691.
12.
Fosså, Alexander, Helen Goergen, Peter Kamper, et al.. (2018). B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and predniso(lo)Ne) in Older Patients with Advanced-Stage Hodgkin Lymphoma: Results of a Phase II Intergroup Trial By the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG). Kölner Universitäts PublikationsServer (Universität zu Köln).
13.
Kinch, Amelie, Christer Sundström, Eva Baecklund, et al.. (2018). Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation. Leukemia & lymphoma. 60(2). 376–384.
14.
Chen, Robert, Pier Luigi Zinzani, Michelle A. Fanale, et al.. (2017). Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma. Journal of Clinical Oncology. 35(19). 2125–2132.
15.
Gormsen, Lars Christian, et al.. (2016). The Importance Of Bone Marrow 18F-Fdg Uptake And Focal Skeletal Lesions On Survival In Patients With Newly Diagnosed Hodgkin Lymphoma. Haematologica. 101. 42–42.
16.
Glimelius, Ingrid, et al.. (2012). Tissue microarray and digital image analysis: a methodological study with special reference to the microenvironment in Hodgkin lymphoma. Histopathology. 61(1). 26–32.
17.
Simard, Julia F., Eva Baecklund, Amelie Kinch, et al.. (2010). Pediatric Organ Transplantation and Risk of Premalignant and Malignant Tumors in Sweden. American Journal of Transplantation. 11(1). 146–151.
18.
Biggar, Robert J., Julia S. Johansen, Karin E. Smedby, et al.. (2008). Serum YKL-40 and interleukin 6 levels in Hodgkin lymphoma. QUT ePrints (Queensland University of Technology).
19.
Enblad, Gunilla, Daniel Molin, Ingrid Glimelius, Marie Fischer, & Gunnar Nilsson. (2007). The Potential Role of Innate Immunity in the Pathogenesis of Hodgkin's Lymphoma. Hematology/Oncology Clinics of North America. 21(5). 805–823.
20.
Molin, Daniel, Gunilla Enblad, Anita Gustavsson, et al.. (2003). Early and intermediate stage Hodgkin's lymphoma – report from the Swedish National Care Programme. European Journal Of Haematology. 70(3). 172–180.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Naomi Hunder Breakdown of academic impact, for papers by Kay M. Ristow Breakdown of academic impact, for papers by Jacques Bosq Breakdown of academic impact, for papers by Joke W. Baars Breakdown of academic impact, for papers by J. Bosq Breakdown of academic impact, for papers by Andreas Zettl Breakdown of academic impact, for papers by Ryo Ichinohasama Breakdown of academic impact, for papers by Ayoma D. Attygalle Breakdown of academic impact, for papers by Janet Matthews Breakdown of academic impact, for papers by Luís Colomo